Menopause Review (Feb 2011)
Kliniczne aspekty atrofii urogenitalnej u kobiet
Abstract
Female urogenital atrophy increases with the menopausal age. It is also susceptible to various types ofhormonal therapy, e.g. systemic menopausal hormonal therapy and vaginal hormone therapy. Tibolone,a synthetic steroid with the affinity to all the basic types of steroid receptors – oestrogen, progesterone andandrogen, is a good (i.e. effective and safe) alternative option to other therapies of atrophic lesions of the lowerurogenital tract in women.